1 Table of Contents 1.1 List of Tables 1.2 List of Figures 2 Executive Summary 2.1 Sales for the POC Diagnostics Market 2.2 Market Dynamics 2.3 Key Players in the POC Diagnostics Market 2.4 POC Diagnostics Market Future Outlook 2.5 What Do Physicians Think? 3 Introduction 3.1 Catalyst 3.2 Related Reports 4 Industry Overview 4.1 POC Diagnostics Overview 4.2 Test Trends 4.2.1 Cardiac Markers POC Testing 4.2.2 Female Fertility and Pregnancy POC Testing 4.3 Mergers, Acquisitions, and Key Partnerships 5 Unmet Needs 5.1 Detection of Multiple Analytes 5.2 Sensitivity of Lateral Flow Technology 5.3 Analytical Quality 5.4 Markers for Myocardial Ischemia 5.5 Data Management 5.6 POC Diagnostics to Reduce Usage of Antibiotics 5.7 Cost-Effectiveness and Reimbursement 5.8 Gap between Physicians and Manufacturers 6 Market Drivers and Barriers 6.1 Drivers 6.1.1 Fast Turnaround Time 6.1.2 POC Molecular Testing Driving Infectious Disease POCT 6.1.3 Increasing Adoption of Cardiac Marker POCT 6.1.4 Expansion POC Testing Menu 6.1.5 Expansion of the Home-Testing Market 6.1.6 CLIA Waived Status for POCT 6.1.7 Rising Prevalence of Diseases 6.2 Barriers 6.2.1 Management of POCT 6.2.2 Competition with Laboratory Tests 6.2.3 Regulatory Compliance 6.2.4 Medical Device Excise Tax 7 Competitive Assessment 7.1 Company Share Analysis 7.1.1 US 7.2 Trends in Corporate Strategy 7.3 Major Players 7.3.1 Abbott Diagnostics 7.3.2 Akers Bioscience 7.3.3 Alere 7.3.4 Beckman Coulter 7.3.5 BioMerieux 7.3.6 Chembio Diagnostics 7.3.7 EKF Diagnostics 7.3.8 Meridian Bioscience 7.3.9 OraSure Technologies 7.3.10 Quidel 7.3.11 Radiometer Medical 7.3.12 Response Biomedical 7.3.13 Roche Diagnostics 7.3.14 Siemens Healthcare 7.3.15 Trinity Biotech 7.3.16 Other Companies 8 Pipeline Assessment 8.1 Overview 8.2 Pipeline Profiles 8.2.1 Cardiac Markers POCT 8.2.2 Female Fertility and Pregnancy POCT 8.2.3 Hematology POCT 8.2.4 Infectious Disease POCT 8.2.5 Immunochemistry POCT Analyzers 9 Market Outlook 9.1 US 9.1.1 Overview 9.1.2 Market Analysis 10 Appendix 10.1 Bibliography 10.2 Abbreviations 10.3 Report Methodology 10.3.1 Overview 10.3.2 Coverage 10.3.3 Secondary Research 10.3.4 Forecasting Methodology 10.3.5 Primary Research — Key Opinion Leader Interviews 10.3.6 Primary Research - Physician and Industry Interviews 10.3.7 Expert Panel Validation 10.4 Physicians and Specialists Included in This Study 10.5 About the Authors 10.5.1 Analysts 10.5.2 Tyler Fletcher, Global Head of Medical Devices 10.6 About MediPoint 10.7 About GlobalData 10.8 Contact Us 10.9 Disclaimer

1.1 List of Tables Table 1: POC Diagnostics: Key Metrics in the US, 2015-2021 Table 2: Advantages and Disadvantages of POCT Table 3: US Troponin POCT Volume (thousands) Forecast, 2012-2021 Table 4: US B-type Natriuretic Peptide POCT Volume (thousands) Forecast, 2012-2021 Table 5: US Follicle-Stimulating Hormone POCT Volume Forecast, 2012-2021 Table 6: US Luteinizing Hormone POCT Volume (thousands) Forecast, 2012-2021 Table 7: US Human Chorionic Gonadotropin POCT Volume (thousands) Forecast, 2012-2021 Table 8: Mergers, Acquisitions, and Key Partnerships, 2012-2016 Table 9: Company Profile - Abbott Diagnostics Table 10: Abbott Diagnostics’ POC Portfolio Assessment, 2015 Table 11: SWOT Analysis - Abbott Diagnostics Table 12: Company Profile - Akers Bioscience Table 13: Aker Bioscience’s POC Portfolio Assessment, 2015 Table 14: SWOT Analysis - Akers Bioscience Table 15: Company Profile - Alere Table 16: Alere’s POC Portfolio Assessment, 2015 Table 17: SWOT Analysis - Alere Table 18: Company Profile - Beckman Coulter Table 19: Beckman Coulter’s POC Portfolio Assessment, 2015 Table 20: SWOT Analysis - Beckman Coulter Table 21: Company Profile - BioMerieux Table 22: BioMerieux’s POC Portfolio Assessment, 2015 Table 23: SWOT Analysis - BioMerieux Table 24: Company Profile - Chembio Diagnostics Table 25: Chembio Diagnostics’ POC Portfolio Assessment, 2015 Table 26: SWOT Analysis - Chembio Diagnostics Table 27: Company Profile - EKF Diagnostics Table 28: EKF Diagnostics’ POC Portfolio Assessment, 2015 Table 29: SWOT Analysis - EKF Diagnostics Table 30: Company Profile - Meridian Bioscience Table 31: Meridian Bioscience’s POC Portfolio Assessment, 2015 Table 32: SWOT Analysis - Meridian Bioscience Table 33: Company Profile - OraSure Technologies Table 34: OraSure Technologies’ POC Portfolio Assessment, 2015 Table 35: SWOT Analysis - OraSure Technologies Table 36: Company Profile - Quidel Table 37: Quidel’s POC Portfolio Assessment, 2015 Table 38: SWOT Analysis - Quidel Table 39: Company Profile - Radiometer Medical Table 40: Radiometer Medical’s POC Portfolio Assessment, 2015 Table 41: SWOT Analysis - Radiometer Medical Table 42: Company Profile - Response Biomedical Table 43: Response Biomedical’s POC Portfolio Assessment, 2015 Table 44: SWOT Analysis - Response Biomedical Table 45: Company Profile - Roche Diagnostics Table 46: Roche Diagnostics’ POC Portfolio Assessment, 2015 Table 47: SWOT Analysis - Roche Diagnostics Table 48: Company Profile - Siemens Healthcare Table 49: Siemens Healthcare’s POC Portfolio Assessment, 2015 Table 50: SWOT Analysis - Siemens Healthcare Table 51: Company Profile - Trinity Biotech Table 52: Trinity Biotech’s POC Portfolio Assessment, 2015 Table 53: SWOT Analysis - Trinity Biotech Table 54: Other POC Companies in North America, 2015 Table 55: Other POC Companies in Europe, 2015 Table 56: Other POC Companies in APAC and Other Regions, 2015 Table 57: Key Cardiac Markers POCT Pipelines, 2015 Table 58: Key Female Fertility and Pregnancy POCT Pipelines, 2015 Table 59: Key Hematology POCT Pipelines, 2015 Table 60: Key Infectious Disease POCT Pipelines, 2015 Table 61: Key Immunochemistry POCT Analyzer Pipelines, 2015 Table 62: US POC Diagnostics Sales Forecast ($m), 2012-2021 Table 63: POC Diagnostics - Primary Call Count 1.2 List of Figures Figure 1: POC Diagnostics Market Revenue, US, 2015 and 2021 Figure 2: Troponin POCT Volume, 2012-2021 Figure 3: B-type Natriuretic Peptide POCT Volume, 2012-2021 Figure 4: Follicle-Stimulating Hormone POCT Volume, 2012-2021 Figure 5: Luteinizing Hormone POCT Volume, 2012-2021 Figure 6: Human Chorionic Gonadotropin POCT Volume, 2012-2021 Figure 7: US POC Diagnostics Market, By Company Share, 2015 Figure 8: US POC Diagnostics Sales Forecast ($m), 2012-2021 Figure 9: US POC Diagnostics Market Revenue Breakdown, by Segment, 2015 Figure 10: POC Diagnostics - Primary Call Count (N=390)

Abbott Diagnostics Akers Bioscience Alere Beckman Coulter BioMerieux Chembio Diagnostics EKF Diagnostics Meridian Bioscience OraSure Technologies Quidel Radiometer Medical Response Biomedical Roche Diagnostics Siemens Healthcare Trinity Biotech